Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10483679 | 0.88 | ELANE (1.00) | ELANEKDM4EMAPTMAPK1CA2 | |
| SCHEMBL22279608 | 0.87 | ELANE (0.60) | ELANEKDM4EALDH1A1USP2HPGD | |
| SCHEMBL11334017 | 0.87 | ELANE (0.64) | ELANEKDM4EALDH1A1CA2 | |
| SCHEMBL10483738 | 0.83 | ELANE (1.00) | ELANEMAPTMAPK1 | |
| SCHEMBL10483733 | 0.83 | ELANE (1.00) | ELANEMAPTMAPK1 | |
| SCHEMBL5306075 | 0.82 | ALDH1A1 (0.63) | ELANEKDM4EALDH1A1USP2HPGD | |
| SCHEMBL7780229 | 0.82 | ELANE (0.58) | ELANEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19718952 | 0.79 | ELANE (0.68) | ELANECA2 | |
| SCHEMBL4790029 | 0.78 | ELANE (0.63) | ELANEALDH1A1MAPK1 | |
| SCHEMBL1914540 | 0.77 | ELANE (0.77) | ELANEKDM4EALDH1A1USP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | ELANE 1482/4885KDM4E 2460/4885ALDH1A1 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.